20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Eikon Therapeutics, Inc. Common Stock (EIKN) operates in the BIOTECHNOLOGY industry and is headquartered in Millbrae, United States with about 384 employees. Its market capitalization is roughly $288 million. In the fiscal year ended 2025-12-31, EIKN reported $0M in revenue and ($324M) in net income.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($24M) | — | — |
| Gross Margin % | — | — | — | — |
| Operating Income (EBIT) | ($339M) | ($339M) | ($260M) | ($266M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($322M) | ($324M) | ($244M) | ($242M) |
| Net Margin % | — | — | — | — |
| EBITDA | ($297M) | ($299M) | ($218M) | ($224M) |
| Earnings Per Share (EPS) | $-5.95 | $-5.99 | $-4.52 | $-4.48 |
| Shares Outstanding (M) | 54M | 54M | 54M | 54M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | ($5M) | ($5M) | ($5M) | — | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($93M) | ($87M) | ($83M) | ($75M) | ($110M) | ($71M) | ($68M) |
| Operating Margin % | — | — | — | — | — | — | — |
| Net Income | ($88M) | ($83M) | ($80M) | ($71M) | ($105M) | ($68M) | ($65M) |
| Net Margin % | — | — | — | — | — | — | — |
| EBITDA | ($88M) | ($78M) | ($75M) | ($56M) | ($103M) | — | — |
| Earnings Per Share (EPS) | $-1.63 | $-1.53 | $-1.47 | $-1.32 | — | — | $-1.20 |
| Shares Outstanding (M) | 54M | 54M | 54M | 54M | — | — | 54M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($256M) | ($189M) | ($135M) | ($191M) |
| Capital Expenditures (CapEx) | $3M | $47M | $85M | $29M |
| Free Cash Flow (FCF) | ($259M) | ($235M) | ($220M) | ($219M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($65M) | ($90M) | ($42M) | ($60M) | ($33M) | ($55M) | ($24M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $3M | $22M | $22M | $40M |
| Free Cash Flow (FCF) | ($65M) | ($90M) | ($42M) | ($62M) | ($54M) | ($77M) | ($63M) |
| FCF Margin % | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets | $780M | $595M | $491M | $526M |
| Cash & Cash Equivalents | $143M | $105M | $129M | $113M |
| Total Liabilities | $313M | $1.5B | $1.1B | $867M |
| Total Debt (Short + Long-Term) | $9M | $10M | $0M | $0M |
| Total Shareholders' Equity | $466M | ($879M) | ($572M) | ($341M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EIKN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms